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vested and spliced longitudinally to be used as an inter-
position cuff between the IVC and LRV. A partial-
occlusion clamp was then placed across the IVC-LRV
junction. The LRV was divided and the venotomy on the
IVC was extended inferiorly. The superior portion of the
IVC venotomy was sutured. Subsequently, the LRV was
then anastomosed caudally onto the IVC in and end-to-
side fashion with the vein cuff bridging the gap.
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Objectives: Acute limb ischemia (ALI) in infants is a
catastrophic event usually associated with other life
threatening medical problems. Since ALI is rare in the
infant population it presents a clinical conundrum for the
vascular surgeon with regards to management. Here we
report our experience in the management of infant ALI
to provide management guidelines for the vascular
surgeon.
Methods: Retrospective analysis of our vascular sur-
gery database from 2004 - 2010 of infants diagnosed with
ALI.
Results: Twelve infants with a mean age of 3  3
months were identified. There were 11 iatrogenic injuries
and 1 unknown cause of ALI. The most frequent presen-
tations were cyanotic limbs (n8) and pulselessness (n6).
The lower extremities were most commonly involved
(n9). The most common arterial sites of occlusion were
CFA (n6), SFA (n3), and radial arteries (n2).
Eleven patients were treated conservatively with systemic
heparin (n8), intra-muscular enoxaparin (n2) and
anti-platelet treatment (n1). One patient was treated
surgically with Fogarty balloon thrombectomy of the
CFA. There were three deaths all due to associated
comorbidities. The one surgically managed patient died
30 days after intervention due to septic complications.
Follow up was available on seven of nine survivors. All
had palpable pulses present and viable limbs on fol-
low-up examination (mean 20  14 months, range
5-42). There were three complications in the patients
managed conservatively: loss of fingernails (1), skin ne-
crosis requiring debridement (1), and maldevelopment
of the foot (1). None of the patients required amputa-
tion due to conservative management.
Conclusions: Limb viability was 100% in this series of
infant ALI managed non-operatively, which reflects the po-
tential of collateral vessel formation and recanalization of
thrombosed vessels in this patient population. Our recom-
mendation for infants presenting with ALI is conservative
observation with anti-coagulation and intervention only for
cases with tissue loss.
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Objectives: The randomized DECREASE III trial
showed that perioperative statin use is associated with a
significant reduction of perioperative cardiovascular
events. However, the potential long-term benefit of
starting statins preoperatively is not well described. The
aim of this study was to establish whether preoperative
initation of statin therapy also results in a long-term
survival benefit compared to postoperative initiation of
statin therapy.
Methods: The DECREASE III trial was a double blind
randomized trial including vascular surgery patients, compar-
ing placebo and fluvastatin use in the perioperative period.
Treatment started amedian of 34 days prior to surgery. At the
end of the study period, i.e. at the outpatient clinic visit 30
days after surgery, all patients were prescribed life-long statins
as recommended by current guidelines. The endpoint of the
current analysis was all-cause death, ascertained by contacting
the civil service registry.
Figure 1. Long-term outcome of patients on perioperative statin
therapy vs placebo.
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